- Home
- PHAR vs EIM Comparison
PHAR vs EIM Comparison
Compare PHAR & EIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- EIM
- Stock Information
- Founded
- PHAR 1988
- EIM 2002
- Country
- PHAR Netherlands
- EIM United States
- Employees
- PHAR N/A
- EIM N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- EIM Finance/Investors Services
- Sector
- PHAR Health Care
- EIM Finance
- Exchange
- PHAR Nasdaq
- EIM Nasdaq
- Market Cap
- PHAR 731.1M
- EIM 522.9M
- IPO Year
- PHAR N/A
- EIM N/A
- Fundamental
- Price
- PHAR $10.42
- EIM $9.51
- Analyst Decision
- PHAR Strong Buy
- EIM
- Analyst Count
- PHAR 3
- EIM 0
- Target Price
- PHAR $30.00
- EIM N/A
- AVG Volume (30 Days)
- PHAR 3.5K
- EIM 215.2K
- Earning Date
- PHAR 07-31-2025
- EIM 01-01-0001
- Dividend Yield
- PHAR N/A
- EIM 4.32%
- EPS Growth
- PHAR N/A
- EIM N/A
- EPS
- PHAR N/A
- EIM N/A
- Revenue
- PHAR $320,708,000.00
- EIM N/A
- Revenue This Year
- PHAR $13.31
- EIM N/A
- Revenue Next Year
- PHAR $7.68
- EIM N/A
- P/E Ratio
- PHAR N/A
- EIM N/A
- Revenue Growth
- PHAR 24.13
- EIM N/A
- 52 Week Low
- PHAR $6.65
- EIM $8.61
- 52 Week High
- PHAR $12.61
- EIM $10.51
- Technical
- Relative Strength Index (RSI)
- PHAR 48.06
- EIM 39.29
- Support Level
- PHAR $9.99
- EIM $9.48
- Resistance Level
- PHAR $10.49
- EIM $9.55
- Average True Range (ATR)
- PHAR 0.33
- EIM 0.05
- MACD
- PHAR -0.11
- EIM -0.01
- Stochastic Oscillator
- PHAR 29.19
- EIM 12.50
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About EIM Eaton Vance Municipal Bond
Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.